

Supplementary Material

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMAC

- Article Title: Adherence to Antidepressants Is Associated With Lower Mortality: A 4-Year Population-Based Cohort Study
- Author(s): Amir Krivoy, MD; Ran D. Balicer MD, PhD; Becca Feldman, PhD; Moshe Hoshen, PhD; Gil Zalsman, MD, MHA; Abraham Weizman, MD; and Gal Shoval, MD
- DOI Number: dx.doi.org/10.4088/JCP.14m09531

List of Supplementary Material for the article

- 1. <u>eTable 1</u> Previous studies examining the association between antidepressant use and all-cause mortality
- 2. <u>eFigure 1</u> Polynomial regression model of mortality hazard by continuous adherence level, adjusted for age, gender, smoking status, socioeconomic status and Charlson comorbidity score
- 3. <u>eFigure 2</u> Polynomial regression model of mortality hazard by continuous adherence level across gender, smoking status, and age group
- 4. <u>eFigure 3</u> Relative hazard ratios for mortality and 95% CIs across clustered adherence levels during 4 years of follow-up
- 5. <u>eTable 2</u> List of antidepressants and ATC codes and summary of users according to drug group
- 6. <u>eFigure 4</u> Polynomial regression model of mortality hazard by continuous adherence level, adjusted for age, gender, smoking status, socioeconomic status, and Charlson Comorbidity Score of population with chronic depression diagnosis:

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2016 Physicians Postgraduate Press, Inc.

Supplementary Table 1: Previous studies examining the association between antidepressants use and all-cause mortality

^a HR for Selective Serotonin Reuptake Inhibitors:1.26 and for Other AD:1.67

^b HR 1.22 for AD use and no dep., HR 2.97 for AD use with dep. compared to no AD use and no dep.

^c HR For tricyclic antidepressant:0.5 and for Other AD:0.66

^d Risk ratio for mortality of AD users vs. AD non users during 1 year.

Study	Ν	Sample	Country	variable	Maximal	Covariates	HR for
					follow-up		mortality
					period		
Scherrer et al. ³³	4,037	Post-MI & Dep.	USA	<12 wk. AD	7 yrs	SDV, Anxiety, HSU	0.33
Gallo et al. ³⁵	1,226	age>60 yrs & Dep.	USA	AD use vs. none	5 yrs	SDV, SmS, CCI, cognition, and suicidal ideation	0.67
Tiihonen et al. ²⁶	15,390	Hospitalized suicide attempters	Finland	AD use vs. none	7 yrs	SDV, no. of previous AD prescriptions, and no. of previous suicide attempts	0.64

Berkman et al. ³⁴	2,481	Post-MI &	USA	AD use vs. none	5 yrs	Age, baseline BDI score, Killip class,	NS
		Dep.				ejection fraction, creatinine level,	
						previous MI, prior medical diagnoses	
Glassman et al. ³⁹	361	Acute	USA	AD use vs. none	7 yrs	Age, gender	0.42
		coronary					
		syndrome &					
		Dep.					
Coupland et al. ²⁴	60,746	age>65 yrs	UK	AD class use vs.	12 yrs	SDV, previous dep., severity of index	1.16-1.67 ^a
		& Dep.		none		Dep., deprivation, SmS, comorbidities, use of other drugs and previous falls	
Almeida et al. ³⁶	5,276	68-88 yrs,	Australia	AD use -/+ dep.	7 yrs	age, education, migrant status,	1.22-2.97 ^b
		men +/-		vs. no AD no dep.		physical activity, SmS, alcohol use	
		Dep.				and CCI	
Ryan et al. ³⁷	7,363	Elderly	France	AD use vs. none	4 yr	SDV, cognition, alcohol consumption,	2.22
						SmS, disability, recent hospitalization,	
						comorbidity, weight	
Scherrer et al. 40	93,653	Dep. w/o	USA	AD class 12 wk.	7 yrs	SDV, Anxiety, Cardio-vascular	0.5-0.66 ^c
		cardiac		use vs. less		indices, Dep. severity	
		disease					
Bingefors et al. 41	456	AD	Sweden	AD use vs. none	9 yrs	SDV, physical diseases	1.52

	AD vs.	prescribed					
	912	vs. MC					
	MC						
Sundell et al. ²⁵	94,239	Age 20-34	Sweden	AD use vs. none	1 yr	Gender	4.39 ^d

MI – Myocardial Infarction. Dep. – Depression, AD – Antidepressants, wk – Week, SDV – Socio-Demographic Variables,

HSU – Health Service Utilization, SmS - Smoking Status, CCI – Charlson Comorbidity Index, MC – Matched control,

HR – Hazard ratio, NS- Non Significant





Figure 1: Polynomial regression model of mortality hazard by continuous adherence level, adjusted for age, gender, smoking status, socioeconomic status and Charlson comorbidity score: a) population with follow-up time of three months or more (n=236,262). b) Population with follow-up time of 18 months or more (n=166,812).






Figure 2S: Polynomial regression model of mortality hazard by continuous adherence level across: a) gender b) smoking status c) age group

Supplementary figure 3




Figure 3s: Relative hazard ratios (HR) for mortality and 95% confidence intervals across clustered adherence levels during 4 years follow-up (N=251,745). Non adherence level (<20%) serves as the reference. Adjusted for sex, age, smoking status, socio-economic status and Charlson's comorbidity score


Supplementary Table 2: List of antidepressants and ATC codes and summary of users

according to drug group.

DESIPRAMINE	N06AA01
IMIPRAMINE	N06AA02
CLOMIPRAMINE	N06AA04
OPIPRAMOL	N06AA05
DIBENZEPIN	N06AA08
AMITRIPTYLINE	N06AA09
NORTRIPTYLINE	N06AA10
DOXEPIN	N06AA12
MAPROTILINE	N06AA21
FLUOXETINE	N06AB03
CITALOPRAM	N06AB04
PAROXETINE	N06AB05
SERTRALINE	N06AB06
FLUVOXAMINE	N06AB08
ESCITALOPRAM	N06AB10
PHENELZINE	N06AF03
MOCLOBEMIDE	N06AG02
MIANSERIN	N06AX03
TRAZODONE	N06AX05
MIRTAZAPINE	N06AX11
BUPROPION	N06AX12
VENLAFAXINE	N06AX16
MILNACIPRAN	N06AX17
REBOXETINE	N06AX18
DULOXETINE	N06AX21
ST. JOHN'S	
WORT	N06AX30
Drug group	
SSRI	

Drug group	n	%
SS <i>RI</i>	192697	44.9
SNRI	35951	8.4
TCA	84761	19.7
MAO	123	0.0
Others	5021	1.2





b)




Figure 4: Polynomial regression model of mortality hazard by continuous adherence level, adjusted for age, gender, smoking status, socioeconomic status and Charlson's comorbidity score of population with chronic Depression diagnosis: a) entire population (n=93,446). b) Sub-population (n=77,157) with more than 6 months of prescription